AgomAb Therapeutics NV ADR(AGMB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 25.98% | Shs Outstand | 48.7M | Perf Week | -11.94% |
| Market Cap | 0.64B | Forward P/E | - | EPS next Y | -17.58% | Insider Trans | - | Shs Float | 36.5M | Perf Month | -7.44% |
| Enterprise Value | 0.36B | PEG | - | EPS next Q | -0.43 | Inst Own | 26.72% | Short Float | 2.41% | Perf Quarter | 32.19% |
| Income | - | P/S | - | EPS this Y | 98.93% | Inst Trans | 0.05% | Short Ratio | 7.23 | Perf Half Y | -6.11% |
| Sales | - | P/B | 2.12 | EPS next 5Y | 76.28% | ROA | - | Short Interest | 0.88M | Perf YTD | -11.16% |
| Book/sh | 6.16 | P/C | 2.23 | EPS past 3/5Y | -102.05% - | ROE | - | 52W High | -26.71% ($17.82) | Perf Year | - |
| Cash/sh | 5.85 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 49.26% ($8.75) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 11.86% 8.27% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.88 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 44.74 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.88 | Sales Q/Q | - | SMA20 | -5.72% ($13.85) | Beta | - | Target Price | $37.13 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -2.38% ($13.38) | Rel Volume | 1.62 | Prev Close | $13.94 |
| Employees | 62 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -177.84% - | SMA200 | 2.96% ($12.68) | Avg Volume(3M) | 0.12M | Price | $13.06 |
| IPO | 2026/2/6 | Option/Short | No/Yes | Trades | 2396 | Volume | 196,656 | Change | -6.31% |
Company
AGMB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a clinical-stage biopharmaceutical company targeting fibrosis (fibrosis). It develops novel drug candidates aimed at fibrosis and regeneration pathways in organs, with its pipeline concentrated on areas of significant unmet medical need, including fibrotic strictures in Crohn's disease, idiopathic pulmonary fibrosis, and liver cirrhosis. It is a clinical-stage biotech currently pursuing a recent listing on Nasdaq.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
AGMB makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +98.9% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 26.7%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $643M.
AGMB $643M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is AGMB?
AGMB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AGMB?
The market cap of AGMB is approximately $643M, ranking 3,012 within its sector.
What is the 52-week high and low for AGMB?
AGMB has recorded a 52-week high of $17.82 and a low of $8.75.
